Best Practice & Research Clinical Haematology
Volume 23, Issue 1 , Pages 121-131, March 2010

Signalling to drug resistance in CLL☆

  • Erin Hertlein, PhD

      Affiliations

    • Division of Hematology-Oncology, College of Medicine, Columbus, OH, USA
    • ,
  • John C. Byrd, MD

      Affiliations

    • Division of Hematology-Oncology, College of Medicine, Columbus, OH, USA
    • Division of Medicinal Chemistry, College of Pharmacy, Columbus, OH, USA
    • The Ohio State Comprehensive Cancer Center, Columbus, OH, USA
    • Corresponding Author InformationCorresponding author. B302 Starling-Loving Hall, 320 West 10th Avenue, Columbus, OH 43210, USA. Tel.: +1 614 293-9869; Fax: +1 614 292-3312.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

☆ This work was supported by the CALGB Foundation, D. Warren Brown Foundation, Specialized Center of Research from the Leukemia and Lymphoma Society, P01 CA95426, T325CA009338, T32 CA106196 and P01 CA101956 from National Cancer Institute.

PII: S1521-6926(10)00008-3

doi:10.1016/j.beha.2010.01.007

Best Practice & Research Clinical Haematology
Volume 23, Issue 1 , Pages 121-131, March 2010

Article Tools